checkAd
    Startseite > Aktien > Sangamo Therapeutics > Nachrichten
    Sangamo Therapeutics Aktie
    0,4868
     
    EUR
    +5,90 %
    +0,0271 EUR
    Letzter Kurs 16:43:47 Tradegate
    0,4808
     
    EUR
    10.400 STK
    Geldkurs 18:02:55
    0,4992
     
    EUR
    10.100 STK
    Briefkurs 18:02:55
    ISIN: US8006771062 · WKN: 936386 · SYM: GBY · USA

    Neueste Nachrichten

    Sangamo Therapeutics Announces Pricing of $24.0 Million Registered Direct Offering
    22.03.24 · Business Wire (engl.) · Sangamo Therapeutics
    Sangamo Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results
    13.03.24 · Business Wire (engl.) · Sangamo Therapeutics
    Sangamo Therapeutics Announces Data From Novel Proprietary Neurotropic AAV Capsid Demonstrating Industry-leading Blood-brain Barrier Penetration and Brain Transduction in NHPs
    13.03.24 · Business Wire (engl.) · Sangamo Therapeutics
    Sangamo Therapeutics Announces Fourth Quarter and Full Year 2023 Conference Call and Webcast
    12.03.24 · Business Wire (engl.) · Sangamo Therapeutics
    Sangamo Therapeutics Announces U.S. FDA Alignment on Abbreviated Pathway to Potential Approval and EMA Prime Eligibility for ST-920 in Fabry Disease
    12.02.24 · Business Wire (engl.) · Sangamo Therapeutics
    Sangamo Therapeutics Announces Updated Phase 1/2 STAAR Study Data in Fabry Disease Showing Sustained Benefit and Differentiated Safety Profile
    06.02.24 · Business Wire (engl.) · Sangamo Therapeutics
    Sangamo Therapeutics Announces Strategic Update and Reports Third Quarter 2023 Financial Results
    01.11.23 · Business Wire (engl.) · Sangamo Therapeutics
    Sangamo Therapeutics Announces Third Quarter 2023 Conference Call and Webcast
    25.10.23 · Business Wire (engl.) · Sangamo Therapeutics
    Sangamo Therapeutics to Present Pre-Clinical Data Showcasing Its Epigenetic Regulation for Neurology and CAR-Treg Research at the 30th Annual Congress of the European Society of Gene & Cell Therapy (ESGCT)
    24.10.23 · Business Wire (engl.) · Sangamo Therapeutics
    Sangamo Therapeutics to Present at the Jefferies Cell & Genetic Medicine Summit
    20.09.23 · Business Wire (engl.) · Sangamo Therapeutics
    Sangamo Therapeutics Reports Recent Business Highlights and Second Quarter 2023 Financial Results
    08.08.23 · Business Wire (engl.) · Sangamo Therapeutics
    Sangamo Therapeutics Announces Second Quarter 2023 Conference Call and Webcast
    01.08.23 · Business Wire (engl.) · Sangamo Therapeutics